Sareum - Specialists in Structure-based Drug Discovery - Investors

The Directors of the Company (the “Directors”) have noted the recent speculation on various bulletin boards about the development of the Company’s compounds, in particular Checkpoint Kinase 1 (“Chk1”), its most advanced cancer drug discovery programme.

As reported in the Chairman’s statement which accompanied the Company’s half yearly report for the six months ended 31 December 2008, which was announced on 23 February 2009, the Company has achieved positive results from in-vivo pre-clinical experiments designed to demonstrate that its compounds increase the efficacy of cancer chemotherapeutics that are currently in clinical use. Furthermore, the Company also announced that it had received expressions of interest from pharmaceutical and biotechnology companies in these programmes that it was actively pursuing. Shareholders can view the marketing material relating to the Chk1 licensing opportunity on the Company’s website www.sareum.co.uk.

The Company continues to discuss licensing opportunities with potential partners and further announcements will be made if an agreement is concluded.

The Directors confirm that there is no material information relating to the Company or the development of its compounds which was not previously announced on 23 February 2009.

---ENDS---

Enquiries:

Sareum Holdings plc

Tim Mitchell, Chief Executive Tel: 01223 497 700

John East & Partners Limited, a subsidiary of Merchant Securities PLC (Nomad)

Simon Clements/Bidhi Bhoma Tel: 020 7628 2200

Hybridan LLP (Broker)

Claire Louise Noyce/Stephen Austin Tel: 020 3159 5085